Literature DB >> 24794818

Nicotinamide in Friedreich's ataxia: useful or not?

David R Lynch1, Kenneth H Fischbeck2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24794818      PMCID： PMC4285390          DOI： 10.1016/S0140-6736(14)60573-0

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  7 in total

1.  A rapid, noninvasive immunoassay for frataxin: utility in assessment of Friedreich ataxia.

Authors:  Eric C Deutsch; Avni B Santani; Susan L Perlman; Jennifer M Farmer; Catherine A Stolle; Michael F Marusich; David R Lynch
Journal:  Mol Genet Metab       Date:  2010-07-08       Impact factor: 4.797

Review 2.  Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxia.

Authors:  Joel M Gottesfeld; James R Rusche; Massimo Pandolfo
Journal:  J Neurochem       Date:  2013-08       Impact factor: 5.372

Review 3.  Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

Authors:  Elisabetta Soragni; Chunping Xu; Heather L Plasterer; Vincent Jacques; James R Rusche; Joel M Gottesfeld
Journal:  J Child Neurol       Date:  2012-07-04       Impact factor: 1.987

Review 4.  Friedreich ataxia: the clinical picture.

Authors:  Massimo Pandolfo
Journal:  J Neurol       Date:  2009-03       Impact factor: 4.849

5.  Heterochromatinization induced by GAA-repeat hyperexpansion in Friedreich's ataxia can be reduced upon HDAC inhibition by vitamin B3.

Authors:  Ping K Chan; Raul Torres; Cihangir Yandim; Pui P Law; Sanjay Khadayate; Marta Mauri; Crina Grosan; Nadine Chapman-Rothe; Paola Giunti; Mark Pook; Richard Festenstein
Journal:  Hum Mol Genet       Date:  2013-03-07       Impact factor: 6.150

6.  A0001 in Friedreich ataxia: biochemical characterization and effects in a clinical trial.

Authors:  David R Lynch; Steven M Willi; Robert B Wilson; M Grazia Cotticelli; Karlla W Brigatti; Eric C Deutsch; Olena Kucheruk; William Shrader; Patrice Rioux; Guy Miller; Amale Hawi; Thomas Sciascia
Journal:  Mov Disord       Date:  2012-06-28       Impact factor: 10.338

7.  Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.

Authors:  Vincenzo Libri; Cihangir Yandim; Stavros Athanasopoulos; Naomi Loyse; Theona Natisvili; Pui Pik Law; Ping Kei Chan; Tariq Mohammad; Marta Mauri; Kin Tung Tam; James Leiper; Sophie Piper; Aravind Ramesh; Michael H Parkinson; Les Huson; Paola Giunti; Richard Festenstein
Journal:  Lancet       Date:  2014-04-30       Impact factor: 79.321
  7 in total
  2 in total

1.  Epigenetic therapy for Friedreich ataxia.

Authors:  Elisabetta Soragni; Wenyan Miao; Marco Iudicello; David Jacoby; Stefania De Mercanti; Marinella Clerico; Filomena Longo; Antonio Piga; Sherman Ku; Erica Campau; Jintang Du; Pablo Penalver; Myriam Rai; Joseph C Madara; Kristopher Nazor; Melinda O'Connor; Anton Maximov; Jeanne F Loring; Massimo Pandolfo; Luca Durelli; Joel M Gottesfeld; James R Rusche
Journal:  Ann Neurol       Date:  2014-09-16       Impact factor: 10.422

Review 2.  Meat Intake and the Dose of Vitamin B3 - Nicotinamide: Cause of the Causes of Disease Transitions, Health Divides, and Health Futures?

Authors:  Lisa J Hill; Adrian C Williams
Journal:  Int J Tryptophan Res       Date:  2017-05-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.